Abstract :
Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.
